CD8A and neoplasm: ICBs are thought to “reprogram” CD8+ tumor-infiltrating lymphocytes (CD8+TILs) to produce antitumor responses by targeting inhibitory receptors such as programmed cell death protein 1 (PD-1), which are highly expressed by most CD8+TIL populations [3, 4].